R & d- medical: biomedical (basic research)

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201500053C
Awardee
Awarding agency
Obligated
$977,245

Award facts

Opportunity
  • BAAN44CM4701411 Solicitation number
Contract value 100% obligated
$977,245.04 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Basic Research
Pricing
Cost Plus Fixed Fee
Place of performance
Watertown, MA 02472, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00002 -$14,280
Other Administrative Action 1 · Sbir topic 309 phase II - high density RT-PCR arrays for cancer diagnosis and PROGNOSIS09/22/2015 - 09/21/2017 $0
Original award $991,525

About this award

The National Cancer Institute awarded a definitive contract to Pathrx, Inc. for biomedical basic research under SBIR Topic 309 Phase II on September 22, 2015, with a ceiling value of $977,245.04.

The contract funds research on high-density RT-PCR arrays for cancer diagnosis and prognosis. Performance runs from September 22, 2015 through September 21, 2017, and is priced on a cost-plus-fixed-fee basis. Place of performance is Watertown, MA.

Quick answers

Who was awarded contract HHSN261201500053C?

HHSN261201500053C was awarded to Pathrx, Inc. by National Cancer Institute (National Institutes of Health) on September 22, 2015.

How much is contract HHSN261201500053C worth?

The government has obligated $977,245 on HHSN261201500053C.

Was contract HHSN261201500053C competed?

The extent of competition for HHSN261201500053C was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award